Serum Paraoxonase, Arylesterase, and Glutathione-S-Transferase Activities and Oxidative Stress Levels in Patients with Mushroom Poisoning

Sevki Hakan Eren,1,* Ilhan Korkmaz,1 Fatma Mutlu Kukul Guven,1 Yusuf Kenan Tekin,1 Levent Ozdemir1,3

1Department of Emergency Medicine, Medicine Faculty, Gaziantep University, Gaziantep, Turkey. *Corresponding author. E-mail: shakaneren@hotmail.com

OBJECTIVES: Consumption of toxic species of mushrooms may have detrimental effects and increase oxidative stress. Paraoxonase, arylesterase and glutathione-S-transferase are antioxidants that resist oxidative stress. In this study, we analyzed the changes in these enzymes during intoxication due to mushrooms.

METHODS: The study enrolled 49 adult patients with a diagnosis of mushroom poisoning according to clinical findings and 49 healthy volunteers as the control group. The patients with mild clinical findings were hospitalized due to the possibility that the patient had also eaten the mushrooms and due to clinical findings in the late period, which could be fatal. Paraoxonase, arylesterase, and glutathione-S-transferase concentrations, as well as total antioxidative and oxidant status, were determined in the 49 patients and 49 healthy volunteers by taking blood samples in the emergency department.

RESULTS: While paraoxonase, arylesterase, and total antioxidant status were significantly decreased in the patient group (p < 0.05), glutathione-S-transferase, total oxidant status and the oxidative stress index were significantly higher (p < 0.05). There was a positive correlation between the hospitalization time and the oxidative stress index (r=0.752, p < 0.001), whereas a negative correlation was found with glutathione-S-transferase (r=-0.420, p=0.003).

CONCLUSION: We observed a significant decrease in paraoxonase and arylesterase and an increase in glutathione-S-transferase and oxidative stress indexes in patients with mushroom poisoning, indicating that these patients had an oxidative status. In particular, a low total antioxidative status and high oxidative stress index may gain importance in terms of the assessment of hospitalization duration.

KEYWORDS: Oxidative Stress; Antioxidant Status; Mushroom Poisoning; Emergency Service; Hospitalization Time.

INTRODUCTION

Because they contain nutrients and can easily be obtained from nature, natural mushrooms are commonly consumed all over the world. However, the consumption of some toxic species of mushrooms may cause serious poisoning. Clinically, mushrooms mostly result in gastrointestinal findings and are associated with a good prognosis. Depending on the type of mushroom, different clinical situations involving high mortality rates may occur (1,2).

Paraoxonase (PON) 1 and arylesterase (ARES) are enzymes encoded by the same gene and have similar active centers. PON1, also known as aromatic esterase 1 or serum arylialkylphosphatase 1, is a hydrolase that can hydrolyze paraoxon, a strong inhibitor of cholinesterases, and detoxify other types of organophosphates. The arylesterase enzyme can detoxify organophosphates such as PON1, but it does not exhibit a similar genetic polymorphism. Although the natural substrates of both enzymes are different, the PON1 enzyme can hydrolyze phenyl acetate, a substrate of ARES; therefore, it exhibits the activities of both ARES and PON (3-6). The most prominent feature of ARES enzymes is that they are antioxidants. The serum PON1 enzyme is responsible for a portion of ARES (7,8).

The paraoxonase enzyme system consists of three different groups, namely, PON1, PON2 and PON3. Substrate specificities of enzymes have lactonase activity and vary widely. With lactonase activity, PONs become involved in the metabolism of many drugs and drug precursors. They can also recognize arachidonic acid metabolites as substrates. Additionally, phospholipase A2-like acyl-ARES activities of PON1 have been identified. However, PON2 and PON3 do not have PON activity. PON 3 is reported to have low ARES activity (9-11). The liver has the highest levels of PON expression and activity. The basic synthesis of PON1 and PON3 occurs in the liver. After synthesis, some of the enzymes...
are transferred from the liver to the plasma through a specific transport system (12-14).

Glutathione-S-transferase (GST) is a multi-functional enzyme in humans that is found in many tissues and has a broad activity and specific substrate (15-17).

With this feature, GST performs the task of defense in living organisms exposed to potentially toxic chemicals. GST performs detoxification by neutralizing the electrophilic areas of reduced glutathione, which are related to the sulphydryl group. The resultant product is a water-soluble mercapturic acid that is removed from the body by urinary excretion (18-21). The GST enzyme system performs the detoxification of not only drugs and chemical agents but also some harmful molecules that occur in lipids and DNA, final products of DNA hydroxy peroxides, and alkenol and endogenous electrophilic components (22).

Antioxidants that aim to prevent the damage caused by free radicals consist of enzymes and non-enzyme molecules. The antioxidant/oxidant status of the body can be evaluated by separately measuring the activity of antioxidant enzymes and the concentration of antioxidant/oxidant molecules; however, the general antioxidant/oxidant status can be evaluated more easily by measuring the total antioxidant status (TAS) (23) and overall total oxidant status (TOS) (24). Oxidative stress occurs as a result of excessive oxidant formation in the body, a decrease in the amount of antioxidants or a combination of these situations (4). Factors that increase oxidative stress reduce the activity of some antioxidant enzymes, such as PON1 (25). In this study, we analyzed the level of antioxidant enzymes (PON, ARES, and GST) as well as the TAS, TOS, and oxidative stress index (OSI) in patients with mushroom poisoning who were admitted to our clinic.

We also investigated the correlation of these enzymes (PON, ARES, and GST) with TAS and TOS levels during the hospitalization period.

## MATERIALS AND METHODS

This study was conducted between January 2013 and January 2014 in 49 patients admitted to our university hospital emergency department with mushroom poisoning and 49 healthy volunteers (total of 98 individuals).

Mushroom poisoning diagnosis was made according to the clinical findings in the patients whose symptoms arose within 0-24 hours after ingestion of wild mushrooms while a mycologist was not available to analyze the gastric contents or the mushroom toxins. Clinical signs were cholinergic toxidromes, anticholinergic syndrome, central nervous system signs, early onset of gastrointestinal (GI) symptoms (e.g., cramps, vomiting, and increased bowel activity) and delayed GI symptoms such as hepato-renal toxicity. We also excluded diseases associated with the differential diagnosis (acute kidney injury, acute liver failure, adrenal crisis, bacterial gastroenteritis, food allergies, food poisoning, hallucinogen use, hemorrhagic shock, hepatic encephalopathy, hepato-renal syndrome, isoniazid toxicity, pediatric asthma, septic shock, and viral gastroenteritis) based on the patient history and laboratory results.

A 5-ml sample of blood was obtained from the brachial vein within the first hour following admission for measurement of GST, ARES, and PON1, placed in a sterile vacuum tube, and sent to the biochemistry laboratory. After the blood was centrifuged, the sample was stored in a refrigerator at -80°C. Measurement of serum paraoxonase and ARES activities.

PON1 enzyme activity was performed with a spectrophotometer by measuring the p-nitrophenol absorbance increase within one minute at an ambient temperature of 25°C and wavelength of 412 nm. P-nitrophenol was obtained by paraoxan hydrolysis. The serum PON1 activity determination was performed by modification of the Eckerson, Furlang, Juretic, and Mackness methods (26). Phenyl-acetate was used as a substrate to measure ARES activity. One unit of ARES activity was determined as the µmol phenol that developed within one minute, and the results were expressed as kU/L (27).

### Measurement of serum total antioxidant status

Serum total antioxidants were measured by the automatic measurement method based on the procedure in which the characteristic color formed by the TAS 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) radical was lightened with the antioxidants in the sample (23). The results are expressed as mmol Trolox equivalents/L.

### Measurement of serum total oxidant status

We determined TOS by the automatic measurement method (24). The method involves the conversion of the ferrous ion-o-dianisidine complex in the sample to a ferric ion. The ferric ion forms a colored complex with xylenol orange in an acidic medium. The intensity of color measured by the spectrophotometer is associated with the total quantity of oxidant molecules in the sample. The measurement was calibrated with hydrogen peroxide (H2O2), and the results are expressed as micro-molar H2O2 equivalents per liter (µmol H2O2 equiv./L).

### Determination of GST activity

The volume was increased to 1000 ml by adding 50 µl of 20 mM GSH to 50 µl of 0.2 M sodium phosphate buffer (pH=6.5) and by adding distilled water to 50 µl of 20 mM CDNB and 50 µl of enzyme extract. One unit of enzyme activity is the amount of enzyme that catalyzes 1 µmol product in 1 minute at 30°C, and the activities were calculated based on the increase in the absorbency against the blank at 340 nm and 30°C (28).

OSI was calculated according to the following formula: OSI: TOS/TASx100.

### Statistical analysis

Continuous variables are expressed as the mean ± SD or medians (min-max) in the presence of abnormal distributions, and categorical variables are expressed as percentages. Comparisons between groups of patients were performed using the χ² test for categorical variables, independent samples t test for normally distributed continuous variables, and Mann-Whitney U test when the distribution was skewed. Correlations were evaluated using the Spearman correlation test. The Kruskal-Wallis test was used for comparison of enzyme levels according to the length of hospital stay. All statistical procedures were performed using SPSS software version 14.0 (SPSS Inc., Chicago, IL, USA). A p-value of 0.05 was considered significant.

### Ethics

The study was approved by the Cumhuriyet University Ethics Committee in Sivas, Türkiye (2009-09/85). The study adhered to the tenets of the Declaration of Helsinki.
RESULTS

The difference between the age groups and genders of the patients enrolled in the study was insignificant ($p$ > 0.05).

ARES and PON levels were significantly decreased due to the increased oxidative stress, whereas TOS and GST levels in the patient group increased. When the groups were compared in terms of OSI, the difference between the groups was significant (Table 1).

When the correlation analysis of TAS, TOS, OSI, GST, ARES and PON levels in the patient group was made based on the length of stay, the differences in the TAS, TOS, OSI, and GST levels were significant, while those in the ARES and PON levels were insignificant (Table 2, Figures 1 and 2).

Length of stay was moderately negatively correlated with GST ($r$ = -0.420, $p$ = 0.003; Figure 1), TAS ($r$ = -0.548, $p$ < 0.001), and TOS levels ($r$ = 0.435, $p$ = 0.002) and strongly positively correlated with OSI ($r$ = 0.752, $p$ < 0.001; Figure 2). There was no significant correlation between the length of stay and the other laboratory findings ($p$ > 0.05).

Enzyme levels according to the length of stay are provided in Table 3.

The duration of hospitalization in patients with lower levels of GST was found to be longer.

DISCUSSION

PONs are enzymes with antioxidant effects. PON1 shows a protective effect through the detoxification of neurotoxic agents, such as acute organophosphate insecticides and soman-sarin, and especially against lipid peroxidation, which is very important in atherosclerosis and diabetes pathogenesis. Therefore, it is suggested that increasing the activity and/or concentration of serum PON1 would be useful for the treatment of the disease which increase the oxidative status (29-31).

In a study where PON1 and ARES activities in patients with pulmonary hypertension were examined, both enzymes were reduced depending on oxidative stress, and the results are consistent with those of the present study (7).

In another study, compared with the PON and ARES activities in the patients in the control group, those in the patients with multi-trauma were significantly lower, and it was suggested that consideration of these enzymes in diagnosis and treatment could be useful for assessing the severity of the trauma and the potential effectiveness of the treatment (34). Oxidative stress affects PON1 expression and activity (35). Serum PON1 expression decreases with oxidative stress (36), and PON1 even becomes inactivated under oxidative stress (37).

Table 1 - Baseline characteristics of the study patients.

|                      | Patients (n=49) | Controls (n=49) | $p$  |
|----------------------|----------------|----------------|------|
| Mean age (years)     | 47 ± 15        | 46 ± 13        | 0.657|
| Male/Female          | 27/22          | 25/24          | 0.544|
| TAS                  | 0.8 ± 0.2      | 0.9 ± 0.3      | 0.144|
| TOS                  | 9 (4-18)       | 7 (3-9)        | < 0.001|
| ARES                 | 4421 ± 1292    | 7162 ± 1985    | < 0.001|
| PON                  | 68 ± 24        | 104 ± 42       | < 0.001|
| GST                  | 2.4 (0.6-5.4)  | 1.6 (2.6-5.0)  | 0.002|
| OSI                  | 1.1 (0.4-3.18) | 0.8 (0.3-2.5)  | < 0.001|

Table 2 - Spearman correlation coefficients for the length of stay.

|                      | Length of stay |
|----------------------|----------------|
|                      | $r$            | $p$-value     |
| TAS                  | -0.548         | < 0.001       |
| TOS                  | 0.435          | 0.002         |
| OSI                  | 0.752          | < 0.001       |
| GST                  | -0.420         | 0.003         |
| ARES                 | -0.139         | 0.339         |
| PON                  | 0.042          | 0.776         |

Figure 1 - Correlation between the oxidative stress index and length of stay.

Figure 2 - Correlation between GST and length of stay.
In the study conducted by Eren et al. (2), PON1 enzyme levels of patients with mushroom poisoning were measured at the time of arrival and discharge. The enzyme levels at discharge were found to be higher. The researchers attributed this result to the fact that the enzyme decreased during detoxification during the acute poisoning period and increased again in the following period.

Kati et al. compared the PON, malonyldialdehyde, TAS and ARES levels of 11 patients treated for SSRI poisoning, and while the PON and ARES levels were significantly low, the TAS level was significantly high (38). In our study, consistent with the literature, the PON and ARES levels were significantly lower in the patient group compared with those in the control group. The finding that both enzymes had low levels suggests that they may have been decreased due to their use during the detoxification process. GSTs are an important group of enzymes that eliminate the toxic effects of xenobiotics and electrophilic compounds and thereby prevent alkylation of macromolecules (DNA, RNA, proteins) in cells (39).

GSTs perform the task of detoxification by neutralizing the electrophilic areas of reduced glutathione, which are related to the SH group. In the literature, we did not find any study that investigated the relationship between GST enzymes and intoxication. In some studies, compared with GST enzymes in healthy controls, GST enzymes were significantly higher in patients with complex regional pain syndrome (40). In rats exposed to cold temperatures for a long time, GST enzymes increased intoxication. In some studies, compared with GST enzymes that investigated the relationship between GST enzymes and intoxication. Further studies are required to clarify the possible mechanisms underlying the decreased and increased levels of these factors.

### Limitations

In conclusion, we observed a significant decrease in PON and ARES and an increase in OSI and GST levels in patients with mushroom poisoning, indicating that these patients had an oxidative status. However, these results are not sufficient to explain the relationship between antioxidants and mushroom poisoning. Further studies are required to clarify the possible mechanisms underlying the decreased and increased levels of these factors.

### REFERENCES

1. Berger KJ, Guss DA. Mycotoxins revisited: Part I. J Emerg Med. 2005; 28(1):53-62, http://dx.doi.org/10.1016/j.jemermed.2004.08.013.
2. Eren SH, Korkmaz I, Guven FM, Aydin H, Karadayi S. Paraoxonase levels in acute mushroom poisoning cases treated in emergency department. J Med Plant Res. 2011;5(1):141-3.
3. Kirbas A, Kirbas S, Anlar O, Efe H, Yilmaz A. Serum paraoxonase and arylesterase activity and oxidative status in patients with multiple sclerosis. J Clin Neurosci. 2013;20(8):1106-9, http://dx.doi.org/10.1016/j.jocn.2012.09.020.
4. Kurban S, Akpınar Z, Mehmetoğlu I. Multiple sclerosis hastalarında serum paraksokonaz ve arilesteraz aktiviteleri ile oksidatif stresin araştırılması. Genel Tip Derg. 2010;20(13):13-7.
5. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol. 1996;7(2):69-76, http://dx.doi.org/10.1097/00005344-199604000-00004.
6. Draconov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol. 2004;369(1):78-88, http://dx.doi.org/10.1007/s00210-003-0833-1.
7. Kayra Z, Esmer A, Yıldız A, Yeşiltas AB, Güntekin Ü, Sehen H, et al. Pulmoner Hipertansiyonda Serum Paraoxonaz ve Arilesteraz Aktivitesinin Değerlendirilmesi. TGKD. 2012;16(4):135-40.
8. Canales A, Sánchez-Muniz FJ. Paraoxonase, something more than an enzyme? Med Clin. 2003;121(14):537-48, http://dx.doi.org/10.1016/S0025-7753(03)74011-1.
9. Beltowska J, Wójcicka G, Jamroz A. Effect of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities. J Cardiovasc Pharmacol. 2004;43(1):121-7, http://dx.doi.org/10.1097/0005344-200401100-00018.

### Table 3 - Enzyme levels (mean ± SD) according to the length of stay.

| Length of stay (days) | 1 | 2 | 3 | 4+ | p |
|-----------------------|---|---|---|----|---|
| TAS                   | 0.93 ± 0.23 | 0.89 ± 0.23 | 0.83 ± 0.21 | 0.56 ± 0.19 | 0.00 |
| TOS                   | 7.57 ± 2.90  | 8.83 ± 3.04  | 9.71 ± 1.98  | 11.15 ± 3.39 | 0.02 |
| OSI                   | 0.84 ± 0.35  | 1.05 ± 0.41  | 1.20 ± 0.24  | 2.08 ± 0.51  | 0.00 |
| GST                   | 3.08 ± 1.32  | 2.85 ± 1.16  | 1.99 ± 0.65  | 2.01 ± 0.83  | 0.04 |
| ARES                  | 4489.29 ± 1328.11 | 4650.42 ± 1650.70 | 4098.14 ± 1041.89 | 4326.64 ± 1190.82 | 0.82 |
| PON                   | 67.86 ± 23.48 | 66.42 ± 26.44 | 65.86 ± 22.83 | 69.00 ± 24.29 | 0.99 |
10. Bey L, Areigat E, Sano A, Hamilton MT. Reduced lipopolysaccharide lipase activity in postural skeletal muscle during aging. J Appl Physiol. 2001;91(2):687-92, http://dx.doi.org/10.1152/jappl.2001.91.2.687.

11. Kakatay U, Kayali R, Uzun H. Relation of plasma protein oxidation parameters and paraoxonase activity in the aging population. Clin Exp Med. 2008;8(1):51-7, http://dx.doi.org/10.1016/j.cemped.2010.12.006.

12. Chełchowska M, Ambrozkiewicz J, Gajewska J, Laskowska-Klita T, Leibschang J. The effect of tobacco smoking during pregnancy on plasma oxidant and antioxidant status in mother and newborn. Eur J Obstet Gynecol Reprod Biol. 2011;155(2):132-6, http://dx.doi.org/10.1016/j.ajo.2010.11.008.

13. Costa LG, Vitolone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol. 2005;69(4):541-50, http://dx.doi.org/10.1016/j.bcp.2004.08.027.

14. Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol. 2011;81(3):337-44, http://dx.doi.org/10.1016/j.bcp.2010.11.008.

15. William BJ. Glutathione-S-transferases: An overview. enzymatic basis of Resistance and Arylesterase Levels in Behcet's Disease. Fırat Universitesi Sağlık Bilim Tıp Derg. 2006;20(4):307-15.

16. Yıldırım A, Aslan Ş, Ocak T, Yıldırım S, Kara F, Şahin YN. Serum Paraoxonase / Arylesterase Activities and Macrophage Levels in Trauma Patients. Eurasian J Med. 2007;39:85-8.

17. Peter WH. Purification and partial characterization of human intestinal glutathione S-transferases. Biochem Pharmacol. 1988;37(11):2288-91, http://dx.doi.org/10.1016/S0006-2952(88)90996-5.

18. Vermeulen NP. Analysis of mercapturic acids as a tool in biotransformation, biomonitoring and toxicological studies. “Glutathione-S-transferases and Drug Resistance” Trends in pharmacological sciences. Taylor and Francis; 1990.

19. Zhao Y, Snel CA, Mulder GJ, Pang KS. Localization of glutathione conjugation toward bromosulfolipid in perinatal rat liver. Studies with the multiple indicator dilution technique. Drug Metab Dispos. 1993;21(6):1070-8.

20. Snel CA, Zhao Y, Mulder GJ, Pang KS. Methods for the quantification of bromosulfolipid and its glutathione conjugate in biological fluids. Anal Biochem. 1993;212(2):28-34, http://dx.doi.org/10.1016/0003-2697(93)90432-4.

21. Siğil Y, Çelik Ş, Atalay A. Changes in Liver Cytoplastic Glutathione-S-Transferase and Microsomal Nitrosothiimolamine Dimethylester Activity in Chicks Obtained Following Daminozide Treatment. Turk J Biol. 2000;24(1):119-26.

22. Speck WT, Rosenkranz HS. Intracellular deoxyribonucleic acid-modifying activity of phototherapy lights. Pediatr Res. 1976;10(5):553-5, http://dx.doi.org/10.1203/00006450-197610000-00010.

23. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004;37(4):277-85, http://dx.doi.org/10.1016/j.clinbiochem.2004.08.008.

24. Erel O. A new automated colorimetric method for measuring total antioxidant status. Clin Biochem. 2005;38(12):1103-11, http://dx.doi.org/10.1016/j.clinbiochem.2005.08.008.

25. Nguyen SD, Sok DE. Oxidative inactivation of paraoxonase 1, an antioxidant protein and its effect on antioxidant action. Free Radic Res. 2003;37(12):1319-30, http://dx.doi.org/10.1080/107157603100012351-1.

26. Juretić B, Simeon-Rudolf V, Reiner E, Baricić B, Simeon-Rudolf V, Reiner E, Baricić B, Baricić B. Paraoxonase and Arylesterase Activities in Patients with Rheumatoid Arthritis. Rheumatism. 2007;22(4):132-6.

27. Haagen L, Brock A. A new automated method for phenotyping aryleserases. Anal Biochem. 1993;212(1):28-34, http://dx.doi.org/10.1006/abio.1993.1286.

28. Erel O. Oxidative stress index may play a key role in patients with pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2013;27(4):645-7, http://dx.doi.org/10.1111/j.1468-3083.2012.04463.x.

29. Avira M, Lorenzo M, Billecke S, Erogul J, Sorenson R, Bissaga CR, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999;26(7-8):892-904, http://dx.doi.org/10.1016/S0891-5849(98)00272-X.

30. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84(4):1381-478, http://dx.doi.org/10.1152/physrev.00047.2003.

31. Gür M, Türköç B, Simeon-Rudolf V, Reiner E, Baricić B, Simeon-Rudolf V, Reiner E, Baricić B. Paraoxonase Levels in Behcet Disease. Fırat Universitesi Sağlık Bilim Tıp Derg. 2006;20(4):307-15.

32. Yiğid Küçük AO, Kös K. Paraoxonase: Biochemical Features, Functions and Clinical Importance. Erciyes Med J. 2004;26:75-80.

33. Işık A, Ustündağ B. Paraoxonase and Arylesterase Levels in Behcet’s Disease. Fırat Universitesi Sağlık Bilim Tıp Derg. 2006;20(4):307-15.